Indian Immunologicals to invest Rs 700 crore in Hyderabad for new animal vaccine facility

Indian Immunologicals has announced an investment of about Rs 700 crore to set up a new animal vaccine manufacturing facility in Hyderabad to meet the vaccine security of the nation against economically important diseases such as Foot and Mouth disease (FMD) and other emerging diseases. The facility will create total employment for nearly 750 people, a statement from the company has claimed.

According to the statement, the company is investing in a new greenfield project for the establishment of a veterinary vaccine facility for manufacturing of Foot and Mouth Disease (FMD) vaccine and other animal vaccines. The facility is intended to be a state-of-the-art fully integrated biosafety level 3 (BSL-3) for Drug substance (DS) production and respective fill-finish. The facility will add another 300 million doses/annum of FMD vaccine to its capacity. Production is scheduled to commence in the third year.

In this regard, Dr K Anand Kumar, MD, Indian Immunologicals, and other members of the Executive Leadership team of the company, including Senior Vice Presidents Mukul Gaur and NSN Bhargav, met KT Rama Rao, Minister, Municipal Administration and Urban Development, Industries and Commerce, and Information Technology, Telangana, yesterday, and briefed him on the company’s plans. Jayesh Ranjan, Principal Secretary, Industries and Commerce and Shakthi M Nagappan, Director, Pharma and Lifesciences, Government of Telangana, were also present during the meeting.

Rao said in the statement, “………Hyderabad is already regarded as the “Vaccine Capital of the World,” and this expansion further advances our contribution in terms of global health, not just for humans, but also for animals.”

Dr Kumar mentioned, “IIL is on an aggressive growth path and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines, and, thereby, saving the exchequer and farmers several thousands of crores.”